

Table 1. The effects of different combination treatments of anastrozole and finasteride on prostate volume, prostate weight and prostate index in rats with testosterone induced BPH and naturally aging BPH at different periods (n=264).														
			Age of rat	8W	12W	20W	28W	36W	44W	52W	60W	68W	76W	84W
			Time of intervention	0W	4W	12W	20W	28W	36W	44W	52W	60W	68W	76W
Groups and parameters														
Testosterone induced BPH group (n=132)	Anastrozole treatment subgroup (BPH-A, n=33)	Body weight (g)	354.79 ±9.03	459.50 ±19.70	499.26 ±32.21	627.67 ±131.52	659.23 ±27.42	571.18 ±21.29	573.53 ±70.11	608.64 ±86.47	612.71 ±87.85	599.42 ±93.39	604.27 ±102.62	
		Prostate weight (g)	0.63±0.02	1.40±0.07	1.41±0.06	1.75±0.32	2.22±0.02	2.23±0.03	2.32±0.05	2.40±0.10	2.41±0.08	2.51±0.06	2.52±0.06	
		Prostatic index (%)	0.18±0.01	0.30±0.01	0.29±0.03	0.33±0.01	0.36±0.04	0.34±0.01	0.33±0.03	0.37±0.04	0.36±0.04	0.43±0.08	0.43±0.08	
		Prostate volume (cm³)	0.33±0.04	1.09±0.16	0.96±0.01	0.88±0.02	0.84±0.05	0.8±0.05	0.82±0.05	1.08±0.01	1.12±0.12	1.17±0.05	1.17±0.05	
	Finasteride treatment subgroup (BPH-F, n=33)	Body weight (g)	361.44 ±8.98	449.61 ±19.01	512.77 ±55.99	490.31±24.39	448.85±6.97	459.07 ±13.93	628.41 ±45.80	691.62±118.16	699.08±23.21	699.50 ±30.42	699.02 ±37.90	
		Prostate weight (g)	0.65±0.02	1.33±0.01	1.29±0.03	1.31±0.04	1.29±0.03	1.32±0.04	1.70±0.58	2.34±0.10	2.35±0.10	2.40±0.08	2.44±0.06	
		Prostatic index (%)	0.18±0.01	0.27±0.01	0.25±0.03	0.27±0.01	0.29±0.01	0.32±0.01	0.30±0.01	0.35±0.07	0.34±0.02	0.34±0.03	0.35±0.03	
		Prostate volume (cm³)	0.35±0.04	1.02±0.06	0.85±0.05	0.80±0.06	0.73±0.01	0.66±0.02	0.7±0.02	0.85±0.02	1.00±0.01	1.02±0.01	1.03±0.01	
	Anastrozole + Finasteride treatment subgroup (BPH-A+F, n=33)	Body weight (g)	352.67 ±23.31	421.85 ±14.00	572.33±33.90	549.00±132.12	589.50±30.74	532.50±56.67	544.30±24.77	580.23±142.67	604.5±80.57	595.12 ±43.89	566.18 ±51.69	
		Prostate weight (g)	0.63±0.02	1.26±0.03	1.30±0.02	1.24±0.02	1.24±0.03	1.22±0.02	1.23±0.01	1.27±0.01	1.26±0.01	1.28±0.03	1.29±0.04	
		Prostatic index (%)	0.18±0.01	0.26±0.01	0.23±0.01	0.24±0.06	0.21±0.01	0.23±0.02	0.23±0.01	0.23±0.06	0.21±0.03	0.22±0.02	0.23±0.03	
		Prostate volume (cm³)	0.36±0.02	0.59±0.07	0.68±0.01	0.66±0.02	0.63±0.02	0.57±0.02	0.54±0.07	0.58±0.03	0.58±0.01	0.60±0.01	0.61±0.02	
	Placebo treatment subgroup (BPH-P, n=33)	Body weight (g)	363.62 ±7.58	475.16 ±27.63	444.74±32.45	515.67±3.78	561.88±34.67	590.16±20.71	607.9±62.77	624.95 ±47.95	624.08 ±23.05	607.59 ±25.73	595.43±19.64	
		Prostate weight (g)	0.63±0.01	1.42±0.07	1.82±0.14	2.30±0.08	2.73±0.14	3.03±0.13	3.25±0.15	3.53±0.02	3.69±0.06	3.70±0.05	3.71±0.05	
		Prostatic index (%)	0.18±0.01	0.37±0.05	0.41±0.01	0.45±0.02	0.49±0.01	0.51±0.01	0.54±0.03	0.57±0.04	0.61±0.02	0.61±0.02	0.62±0.01	
		Prostate volume (cm³)	0.34±0.01	1.15±0.21	1.43±0.28	1.50±0.19	1.62±0.20	1.82±0.08	1.81±0.07	1.92±0.11	1.93±0.10	1.86±0.04	1.87±0.05	
Naturally aging BPH control group (n=132)	Anastrozole treatment subgroup (Control-A, n=33)	Body weight (g)	377.64±16.50	412.35±11.32	483.50±32.92	441.95±7.77	615.27±7.64	568.35±8.59	657.42±19.37	643.95±70.24	667.31±59.22	684.37±48.84	676.92±71.17	
		Prostate weight (g)	0.67±0.02	1.13±0.01	1.21±0.04	1.27±0.01	1.89±0.03	2.26±0.01	2.58±0.06	2.72±0.11	2.72±0.13	2.48±0.04	2.55±0.02	
		Prostatic index (%)	0.17±0.01	0.30±0.01	0.32±0.01	0.35±0.01	0.38±0.01	0.4±0.01	0.42±0.05	0.41±0.07	0.41±0.07	0.36±0.03	0.38±0.04	
		Prostate volume (cm³)	0.35±0.07	0.73±0.05	0.73±0.05	0.74±0.02	0.91±0.05	1.03±0.05	1.05±0.03	1.11±0.03	1.16±0.05	1.13±0.02	1.13±0.02	
	Finasteride treatment subgroup (Control-F, n=33)	Body weight (g)	357.08±21.89	462.80±23.59	485.30±55.75	483.87±57.82	473.88±10.83	444.56±4.52	576.85±69.82	728.25±38.38	690.09±28.74	704.43±39.25	711.53±23.82	
		Prostate weight (g)	0.63±0.02	1.13±0.01	1.14±0.03	1.19±0.06	1.26±0.02	1.45±0.03	2.03±0.18	2.27±0.04	2.27±0.03	2.37±0.06	2.42±0.06	
		Prostatic index (%)	0.18±0.01	0.25±0.01	0.24±0.03	0.25±0.03	0.27±0.01	0.30±0.01	0.29±0.03	0.34±0.02	0.34±0.02	0.34±0.02	0.34±0.02	
		Prostate volume (cm³)	0.35±0.07	0.63±0.07	0.72±0.05	0.66±0.02	0.63±0.02	0.58±0.03	0.63±0.01	0.75±0.02	0.86±0.01	0.88±0.02	0.89±0.01	
	Anastrozole + Finasteride treatment subgroup (Control-A+F, n=33)	Body weight (g)	346.73±20.29	444.23±4.10	505.18±24.38	598.73±44.67	577.00±14.66	575.13±51.62	585.96±24.31	644.13±7.32	591±62.79	583.58±33.35	588.24±31.55	
		Prostate weight (g)	0.61±0.06	1.11±0.01	1.11±0.03	1.14±0.05	1.10±0.02	1.09±0.03	1.07±0.01	1.10±0.03	1.12±0.03	1.22±0.02	1.27±0.04	
		Prostatic index (%)	0.18±0.01	0.25±0.01	0.22±0.01	0.19±0.01	0.19±0.01	0.19±0.01	0.18±0.01	0.17±0.01	0.19±0.02	0.21±0.01	0.22±0.01	
		Prostate volume (cm³)	0.32±0.04	0.51±0.09	0.46±0.02	0.44±0.02	0.45±0.01	0.46±0.01	0.51±0.01	0.5±0.03	0.55±0.05	0.57±0.05	0.58±0.05	
	Placebo treatment subgroup (Control-P, n=33)	Body weight (g)	352.27±11.47	472.18±30.18	640.27±48.11	681.99±53.83	647.18±14.61	678.00±61.13	708.54±58.20	678.00±51.82	628.28±50.50	624.56±65.37	633.81±60.53	
		Prostate weight (g)	0.63±0.02	1.21±0.09	1.71±0.12	2.08±0.04	2.34±0.11	2.82±0.13	3.14±0.02	3.33±0.49	3.35±0.44	3.57±0.10	3.61±0.10	
		Prostatic index (%)	0.18±0.01	0.30±0.01	0.33±0.01	0.37±0.01	0.40±0.04	0.42±0.02	0.44±0.04	0.49±0.04	0.56±0.07	0.56±0.07	0.57±0.06	
		Prostate volume (cm³)	0.34±0.01	0.78±0.08	0.83±0.04	0.91±0.07	0.97±0.03	1.1±0.07	1.15±0.04	1.26±0.02	1.30±0.07	1.31±0.07	1.31±0.06	
			<i>F</i>	<i>P</i> -value		<i>F</i>		<i>P</i> -value		<i>F</i>		<i>P</i> -value		
Prostate weight (g)	Block (time)	389.694	<0.001		Prostatic index (%)	Block (time)	138.995	<0.001		Prostate volume (cm³)	Block (time)	407.887	<0.001	
	Group (intervention)	32098.78	<0.001			Group (intervention)	13660.568	<0.001			Group (intervention)	28804.882	<0.001	

Abbreviations: BPH, benign prostatic hyperplasia; BPH-A, testosterone induced BPH-anastrozole treatment subgroup; BPH-F, testosterone induced BPH-finasteride treatment subgroup; BPH-A+F, testosterone induced BPH-anastrozole + finasteride treatment subgroup; BPH-P, testosterone induced BPH-placebo treatment subgroup; Control-A, naturally aging BPH-anastrozole treatment subgroup; Control-F, naturally aging BPH-finasteride treatment subgroup; Control-A+F, naturally aging BPH-anastrozole + finasteride treatment subgroup; Control-P, naturally aging BPH-placebo treatment subgroup; cm, centimetre; g, gram; W, week.

P-values were calculated using the analysis of variance in random blocks.

The boldface represents statistical significance (*P*<0.05).

